Weight-loss drugs like Ozempic and Zepbound might help protect people from health risks related to sleep apnea, a new study ...

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

Cosmo Fowler, M.D., from Emory University in Atlanta, and colleagues examined data from the TriNetX U.S. Collaborative Network to examine whether OSA modifies outcomes in patients with T2DM receiving ...

GLP-RAs significantly improved liver histology, liver fat, and metabolic markers in patients with MASLD, outperforming DDP-4 inhibitors but increasing mild GI side effects.

Novo Nordisk NVO shares fell roughly 4% in pre-market trading today after U.S. President Donald Trump signaled potential ...

(CE) and methionine restriction (MetR) impacts health and leads to weight loss in mice. The authors provided valuable datasets showing that the responses to MR and CE are tissue-specific, while MR and ...

Novo Nordisk NVO continues to derive the bulk of its revenue from its blockbuster semaglutide (GLP-1 RA) therapies, Wegovy ...

This 3-part series looks at the current evidence for the treatment of SUD, alcohol use disorder, and tobacco use disorder.

Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences, Poznan, Poland Background: Euglycemic diabetic ketoacidosis (euDKA) is a rare but potentially life-threatening ...

Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient ...

GLP-1 RAs may have an anti-inflammatory benefit, suggesting potential use in other ocular inflammatory diseases. Patients prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have roughly ...